“Accumulating evidence implicates the endocannabinoid system in the pathophysiology of psychosis.
If the endocannabinoid system plays a role in psychosis pathophysiology, it raises the interesting possibility that pharmacological compounds that modulate this system may have therapeutic value.
Cannabidiol (CBD), a phytocannabinoid constituent of Cannabis sativa, has been heralded as one such potential treatment.
Cannabidiol (CBD), a non-intoxicating constituent of the cannabis plant, has emerged as a potential novel class of antipsychotic with a unique mechanism of action.
In this review, we set out the prospects of CBD as a potential novel treatment for psychotic disorders.
In sum, CBD currently represents a promising potential novel treatment for patients with psychosis.”